Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A number of cutting edge artificial intelligence (AI) technologies will be tested and scaled in the NHS, as the first winners of the AI in Health and Care Award, sharing approximately £50m. The OxNNet toolkit led by Prof Sally Collins in the Nuffield Department of Women's & Reproductive Health, will receive a share of £50M funding from the NIHR. This exciting project seeks to develop a fully automated ultrasound tool to screen for fetal growth restriction (FGR) in the first trimester.

young woman doctor is viewing an ultrasound result

The NHS is committed to becoming a world leader in the use of artificial intelligence (AI) and machine learning and to harness the benefits on offer from the technology that range from faster and more personalised diagnosis to potential efficiencies in screening services. 

Today’s announcement of the AI in Health and Care Award from the National Institute for Health Research (NIHR) will distribute £140m over three years, and AI tools and products will receive a share of funding totalling over £50m. The funding supports a range of technologies at different stages of development, from concepts to first real-world tests to the scaling of AI products to a number of NHS sites to generate further evidence for potential adoption in the NHS. Each product will undergo robust testing and independent evaluation to ensure they are effective, accurate, safe and value for money.

The full story is available on the Nuffield Department of Women's & Reproductive Health website

Similar stories

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Oxford University and partners win government funding to evaluate Paige Prostate Cancer Detection System

A prostate cancer detection software system to help pathologists quickly identify suspicious areas of tissue, developed by Paige, will be investigated in a multicentre clinical study led by Oxford University as part of a successful NHSx Artificial Intelligence Health and Care Award application.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.